^
    1d
    AREN1721: A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Nov 2026
    Trial completion date
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    |
    Opdivo (nivolumab) • Inlyta (axitinib) • ABP 206 (nivolumab biosimilar)
    1d
    KEYNOTE-B61: Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (clinicaltrials.gov)
    P2, N=160, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    1d
    A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea (clinicaltrials.gov)
    P=N/A, N=600, Recruiting, Takeda | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Fruzaqla (fruquintinib)
    1d
    Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial (clinicaltrials.gov)
    P2, N=236, Not yet recruiting, Sun Yat-sen University
    New P2 trial • Head-to-Head
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    2d
    concept: The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Zhejiang University
    New P2 trial • Checkpoint inhibition • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    2d
    Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Universität des Saarlandes | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Jan 2027 | Trial primary completion date: Sep 2025 --> Jan 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    2d
    AAML1831: A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (clinicaltrials.gov)
    P3, N=1186, Recruiting, Children's Oncology Group | Trial completion date: Sep 2027 --> Jun 2029 | Trial primary completion date: Sep 2027 --> Jun 2029
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Xospata (gilteritinib) • etoposide IV • methotrexate • Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation) • mitoxantrone • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • dexrazoxane
    3d
    A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) (clinicaltrials.gov)
    P3, N=703, Completed, Hutchison Medipharma Limited | Active, not recruiting --> Completed
    Trial completion
    |
    paclitaxel • Fruzaqla (fruquintinib)
    3d
    A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Fudan University
    New P2 trial
    |
    Lenvima (lenvatinib) • Enweida (envafolimab)
    4d
    Machine Learning-Based Survival Analysis for Patients Receiving Lenvatinib for Unresectable Hepatocellular Carcinoma. (PubMed, J Hepatocell Carcinoma)
    These models have the potential to guide clinicians' treatment decisions and provide prognostic evaluations. Future prospective studies with larger cohorts, as well as integration of imaging biomarkers are warranted to optimize these predictive models.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    Lenvima (lenvatinib)
    4d
    Long-Term Disease Control With Lenvatinib in Metastatic Malignant Struma Ovarii: A Case Report. (PubMed, Cureus)
    Subsequently, multiple hepatic metastases and pelvic dissemination developed, and conventional chemotherapy including bevacizumab was ineffective...Switching to sorafenib led to further progression, but reintroduction of LVB reduced Tg levels...The patient has survived seven years since recurrence, including six years on LVB. The tumor behaved similarly to poorly differentiated thyroid carcinoma, with Tg levels reflecting disease activity and LVB demonstrating the potential for long-term tumor control.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog) • TG (Thyroglobulin)
    |
    NRAS mutation
    |
    Avastin (bevacizumab) • sorafenib • Lenvima (lenvatinib)